Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation er en hudtilstand, der er karakteriseret ved øget pigmentering i huden efter en betændelse. Postinflammatory hyperpigmentation kan skyldes langvarig soleksponering, betændelse eller andre hudskader, herunder dem, der er relateret til acne. Personer med mørkere hudtoner er generelt mere tilbøjelige til hyperpigmentering ved overdreven soleksponering.
☆ AI Dermatology — Free Service
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) er et hyppigt hudproblem, der opstår efter hudbetændelse eller skade. Det har en tendens til at vare længe og er værre hos mennesker med mørkere hudtoner (Fitzpatrick skin types III–VI). Selvom det ofte bliver bedre af sig selv, kan det tage et stykke tid, så der ofte er behov for længerevarende behandling. Kombination af forskellige behandlinger giver bedst resultat.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatorisk hyperpigmentering er en almindelig følgetilstand af hudbetændelse. Den har en tendens til at påvirke personer med mørkere hud mere alvorligt og hyppigere. Undersøgelser viser, at problemer som postinflammatorisk hyperpigmentering er blandt hovedårsagerne til, at mennesker med mørkere hudtoner søger dermatologisk behandling. Tidlig behandling er afgørende for at håndtere postinflammatorisk hyperpigmentering og starter normalt med at behandle den indledende betændelsestilstand. Første behandlingslinje involverer typisk brug af topiske midler, der lysner huden, sammen med solcreme til beskyttelse. Disse midler, såsom hydroquinone, azelaic acid, kojic acid, arbutin og licorice extracts, kan effektivt reducere overdreven pigmentering. Derudover anvendes retinoider, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine og soy også som depigmenterende midler, og nye behandlinger dukker op. Mens topiske behandlinger normalt er effektive mod hyperpigmentering på overfladeniveau, kan procedurer (laser, chemical peel) være nødvendige ved genstridige tilfælde. Det er vigtigt at være forsigtig med disse behandlinger for at undgå irritation og forværring af postinflammatorisk hyperpigmentering.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
